

Yardena Samuels

CURRICULUM VITAE

January 2023

A. PERSONAL DETAILS

Date of Birth March 5th 1972
Marital Status: Married, two children
Country of Birth: Israel
Citizenship: Israeli and British
Phone: +972 8 934 3631
Email: yardena.samuels@weizmann.ac.il
Home page: <http://www.weizmann.ac.il/mcb/Samuels/>
ORCID ID: 0000-0002-3349-7266

B. EDUCATION

2003-2006 Post-doctoral research with Prof. Bert Vogelstein, Prof. Victor Velculescu, and Prof. Kenneth Kinzler, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, USA
Field of study: Cancer Research

2002-2003 Post-doctoral research with Prof. Xin Lu, Ludwig Institute for Cancer Research, Imperial College, London, UK
Field of study: Cancer Research

1999-2002 Ph.D. under Prof. Xin Lu, Ludwig Institute for Cancer Research, Imperial College, London, UK
Field of study: Cancer Research
Thesis title: ASPP: A Novel Family of Proteins that Specifically Regulates the Apoptotic Function of p53.

1994-1997 M.Sc. under Prof. Yinon Ben-Neriah, Dept. Immunology and Cancer Research Department, Hadassah Medical School, Israel
Field of study: Immunology and Cancer Research
Thesis title: Regulation of T cell Apoptosis Through Pathways that Activate AP-1 and NFκB.

1990-1993 B.Sc. Natural Sciences, Pathology, Newnham College, Cambridge University, Cambridge, UK

C. EMPLOYMENT

2021-present Full Professor at the Dept. of Molecular and Cell Biology, Weizmann Institute of Science, Israel

2013-2021 Associate Professor at the Dept. of Molecular and Cell Biology, Weizmann Institute of Science, Israel

2006-2013 Assistant Professor at the Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, USA

1998-1999 Senior Research Assistant at Intelligene, Biotechnology Company, Jerusalem, Israel

D. ACADEMIC ADMINISTRATION

2022 EACR president Elect

2015-present MICC steering committee

2014-2017 Member of the Weizmann Appointments and Promotion Committee (V9)

2014-2017 Member of the Life Sciences Faculties Appointments and Promotion Committee (LSV9)

2013- 2014 Member of the Life Sciences Faculties Staff Scientists Appointments and Promotion Committee (LSV5)

2013-2014 Member of the Services Committee

2011-2013 Member, NHGRI Non-Tenure Promotion Committee Membership

2011 Transdisciplinary Research Aligned with Public Health Challenges (TRAPHC) focus group member.

2011 Member, NHGRI Bioinformatics Services Advisory Committee

2011 Transdisciplinary Research Aligned with Public Health Challenges (TRAPHC) focus group member

2009-2011 Member, NHGRI Flow Cytometry Core Advisory Committee

2008 Member, Pigment Cell Interest Group

2007 Member, Organizing Committee for NHGRI Investigator Retreat

2007 Member, Reviewer for the Annual NIH National Graduate Student Research Festival

2007 Member, Poster Judge for the Annual NHGRI Scientific Retreat

2006-2009 Member, NHGRI Tenure Track Faculty Search Committee, Cancer Genetics Branch

2013-present Member, PhD thesis committees in WIS: Kotler Eran, Eizenberger Shay, Narunsky Haziza Lian, Sevilla-Sharon Michal, Noronha Ashish, Geller Leore, Solomon Adam, Grunberg Nil, Noy Cohen
In other institutes: Chong Chloe; Michal Bassani's lab, Yakovian Oren ; Eilon Sherman's lab.

2013-present Examiner M.Sc thesis in WIS: Nuta Gal Chaim, Carmel Narin, Friedlander Nitzan, Tishler Hila, Geller Leore.

2008-present Peer reviewer scientific journals: *Science, Nature, Nature Genetics, Nature Medicine, Nature Methods, Nature Cell Biology, Cancer Research, Genome Research, Journal of Investigative Dermatology, Journal of Clinical Investigation, British Journal of Dermatology, Breast Cancer Research, Trends in Biochemical Sciences, Journal Molecular Cancer Therapeutics, BMC Cancer, Cancer Epidemiology, Biomarkers and Prevention, BBA Reviews on Cancer, Journal Molecular Cancer Research, Pigment Cell and Melanoma Research, PLoS Genetics, PNAS, Nature Communications.*

2005-present Reviewer for granting agencies from Israel and abroad: *Kansas Masonic Cancer Center Research Institute, Cancer Research UK, Medical Research Council (MRC) UK, Israel Cancer Research Fund (ICRF), Cancer Research UK, The Wellcome Trust, Tumor Cell Biology Study Section Ad Hoc NIH Reviewer, Harvard Spore, Israeli Science Foundation (ISF), Austrian Academy of Sciences, American Institute for Cancer Research (AICR), US-Israel Binational Science Foundation (BSF).*

E. OTHER APPOINTMENTS

Positions in the academy

- 2015-present Director of the Ekard Institute for Cancer Diagnosis of the Moross Integrated Cancer Center
- 2015-present Director of the Weizmann-Brazil Tumor Bank of the Moross Integrated Cancer Center

Teaching

- 2020 Precision Medicine in Cancer, Hadassah Medical School, Israel
- 2019 Precision Medicine in Cancer, Hadassah Medical School, Israel
- 2011 Whole Exome Sequencing Approaches, NHGRI/NIH
- 1994-1997 Instructor in the Laboratory course of basic microbiology for medical students.
Hebrew University of Jerusalem, Hadassah Medical School, Israel

Membership in Scientific Advisory Boards and Reviewing Tasks

- 2023 Member, Board of Directors, Minna-James-Heineman-Stiftung
- 2022 Member, Cancer Grand Challenges consultation workshop
- 2022 Member, review panel of the German Cancer Research Center (DKFZ)
- 2020-present 8400- Health Network Leadership program
- 2019-present EACR Industry Committee
- 2019-2021 Member of the Scientific Advisory Board of the National Center for Tumour Diseases (NCT)
- 2016-2021 Chair, EACR Travel Fellowship Committee
- 2016-present Elected Member to the EACR Board
- 2016 Reviewer, evaluation of the Helmholtz Institute for Translational Oncology (TRON)
- 2013 Israel Science Foundation
- 2013 Israel Cancer Association
- 2012-2015 Member, The Cancer Genome Atlas (TCGA) Melanoma Tumor Working Group
- 2012-2016 Professional Advisory Panel, Joanna M. Nicolay Melanoma Foundation
- 2011-present Panel of Expert Advisers for the Nature Index

Membership in Editorial Boards

- 2020-present Scientific Editor for *Cancer Discovery*
- 2018-present ESMO Open-Cancer Horizons
- 2012-present Pigment Cell and Melanoma Research
- 2012-2015 Journal of Investigative Dermatology
- 2011-present Frontiers in Cancer Genetics
- 2011-2018 Frontiers in Molecular and Cellular Oncology, Frontiers in Oncology
- 2011-2018 Frontiers in Oncology

F. INTERNATIONAL RECOGNITION

Awards and Prizes

2021	The Michael Bruno Memorial Award
2020	Elected member of EMBO
2020	Estela Medrano Memorial Award
2019	Elected to the European Academy of Cancer Sciences
2017	Youdim Family Prize for Excellence in Cancer Research
2016	Pezcoller Foundation-EACR Cancer Researcher Award
2014	TEVA-Israel Science Foundation Founders Prize
2013	Elected for the <i>Knell Family Professorial Chair</i>
2013	<i>Peter and Patricia Gruber</i> Prize for Scientific Excellence
2011	Pigment Cell and Melanoma Research prize
2009	Genome Technology top 25 Young Investigator Award
2008	NIH Directors Challenge Innovation Award
2008	NIH Bench-to-Bedside Award
2008	The Harry J. Lloyd Charitable Trust Award
2006	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Research day award
2006	Alfred Blalock, Young Investigators' Day award, Johns Hopkins School of Medicine
2003	EMBO Postdoctoral Fellowship

International Organizing Committees

2022	Scientific program director of the Association for Cancer Immunotherapy (CIMI) 2022
2021	Scientific committee member for the EACR-Genomics 2022
2021	Scientific committee member for the EACR 2022 congress
2020	Scientific committee member for the EACR 2021 congress
2020	Member of the scientific committee Broad-ISF 5 th Cell Circuits Symposium
2020	Scientific committee member for the ESMO congress
2020	Cancer, immunology and physiology scientific advisory committee, ILANIT (FISEB)
2019	Scientific committee member for the ESMO congress
2018-2019	Co-organizer, 4 th EACR special conference on Cancer Genomics
2018	Co-organizer, 10 th European Melanoma Workshop
2017-2018	Scientific Committee member for the ESMO Congress.
2017-2018	Member of the scientific committee Broad-ISF 5 th Cell Circuits Symposium
2016-2017	Member of the scientific program committee, AACR Annual Meeting
2016-2017	Co-organizer, 3 rd EACR special conference on Cancer Genomics
2016-2017	Member of the scientific committee Broad-ISF 4 th Cell Circuits Symposium

- 2016-2017 Member of the scientific committee ESMO –EACR annual congress
- 2014-2015 Co-organizer, 2nd EACR special conference on Cancer Genomics
- 2012 Member of the Education Committee, AACR Annual Meeting
- 2012 Member of the Scientific Program Committee, AACR Annual Meeting
- 2010 Member of the Scientific Program Committee, AACR Annual Meeting

Talks at International Meetings (since 2009)

- 2022 Gordon Peters Keynote lecture, Molecular Analysis for Precision Oncology Congress (MAP), Amsterdam, Netherland
- 2022 Keynote lecture, Society for Melanoma Research Annual conference, Glasgow, Scotland
- 2022 Plenary lecture, VIB conference Tumor Heterogeneity, Plasticity and Therapy (2nd edition), Leuven, Belgium
- 2022 Invited talk, 14th International Symposium on Mass Spectrometry in the Health and Life Sciences: Molecular and Cellular Proteomics. Boston, USA
- 2022 Invited talk, 33rd Prezcoller Symposium. What are the obstacles to cancer immunotherapy success? Trento, Italy
- 2022 EMBO Keynote lecture, Translating Biology to Medicine, European Association for Cancer Research (EACR), Seville, Spain
- 2021 Invited talk, Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, Washington, DC., USA
- 2021 Invited talk, EPIC-XS, "Integrating proteomics and genomics technologies", Virtual
- 2021 Chair, organizer and invited speaker, Methods Workshops on Proteomics Methods to Study the Cancer Immuno-peptidome, AACR Annual Meeting 2021
- 2021 Invited talk, Annual Noreen O'Neill Melanoma Symposium, Philadelphia, USA, virtual
- 2021 Invited talk, European Association for Cancer Research (EACR), the American Association for Cancer Research (AACR) and Società Italiana di Cancerologia (SIC), Florence, Italy
- 2021 Invited talk, Israel Society for Cancer Research (ISCR), Israel, virtual
- 2021 Invited talk, Virtual conference on Teams, Institut Pasteur, Cancer & Immunotherapy, Paris
- 2021 Invited talk, European Association for Cancer Research (EACR), Innovative Cancer Science, virtual congress, Torino, Italy
- 2021 Invited talk, Annual Meeting of the American Association for Cancer Research (AACR), virtual
- 2021 Invited talk, Association for Cancer Immunotherapy (CIMI), Mainz, Germany, virtual
- 2020 Invited talk, Annual Meeting of the Society of Melanoma Research, virtual
- 2020 Invited talk, Achilles Therapeutics Limited, UK, virtual
- 2020 Invited talk, The University of Queensland Diamantina Institute, Australia, virtual
- 2020 Invited talk, Georgetown-Lombardi Comprehensive Cancer Center, US, virtual
- 2020 Invited talk, URPP Annual Scientific Meeting, virtual
- 2020 Invited talk, ESMO Congress Annual meeting, virtual

Yardena Samuels, Department of Molecular and Cellular Biology, Weizmann Institute of Science
 Email: yardena.samuels@weizmann.ac.il
 Phone: +972-8-9343631

- 2020 Invited talk, Society for Melanoma Research International Congress, virtual
- 2020 Invited talk, Annual Meeting 2020 of the French Society for Immunology, Paris, France
- 2020 Invited talk, Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
- 2020 Invited talk, AACR Special Conference on Tumor Heterogeneity: From Single-Cells to Clinical Impact, Philadelphia, USA , virtual
- 2020 Invited talk, Association for Cancer Immunotherapy (CIMI)'s Annual Meeting, Mainz, Germany (cancelled due to COVID-19)
- 2020 Invited talk, Keystone Symposia, Inflammation, Microbiota and Cancer, Taipei, Taiwan (cancelled due to COVID-19)
- 2020 WIS-NKI meeting, Amsterdam, Netherlands (cancelled due to COVID-19)
- 2020 Keynote, Invited talk (virtual due to COVID-19), European Association for Cancer Research (EACR), Torino, Italy
- 2020 Invited talk, 10th European Melanoma Workshop, Nice, France (cancelled due to COVID-19)
- 2019 Invited talk, (ESMO), Cancer Research UK (CRUK) and UNICANCER, London, UK
- 2019 Invited talk, Melanoma Research Alliance, Washington DC, USA
- 2019 Invited talk, ESMO Congress Annual meeting, Madrid, Spain
- 2019 Invited talk Association for Cancer Immunotherapy (CIMI), and the American Association for Cancer Research (AACR) organizations, 5th International Cancer Immunotherapy Conference, Paris, France
- 2019 Invited talk, European Association for Cancer Research (EACR), Cancer Genomics, Cambridge, UK
- 2019 Invited talk, ISCORT, Eilat, Israel
- 2018 Invited talk, Broad-Israel Science Foundation (ISF) Symposium, Boston, MA, USA
- 2018 Invited keynote talk, The European Academy for Biomedical Science (ENABLE), Copenhagen, Denmark
- 2018 Keystone symposia on Precision Medicine in Cancer, Stockholm, Sweden
- 2018 Invited talk, DKFZ, Frontiers in Cancer Research, Heidelberg, Germany
- 2018 Invited talk, Society for Melanoma Research 2018 International Congress, Manchester, UK
- 2018 Invited talk, The 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, the Netherlands
- 2017 Invited talk, European Association for Cancer Research (EACR), Barcelona, Spain
- 2017 Invited talk, FISEB Congress (ILANIT), Eilat, Israel
- 2017 Invited talk, European Association for Cancer Research (EACR), Cambridge, UK
- 2017 Invited talk, EACR-AACR-SIC Special Conference, Florence, Italy
- 2017 Invited talk, 9th European Melanoma Workshop, Sestri Levante, Italy
- 2016 Invited talk, American Association for Cancer Research (AACR), Annual Meeting, New Orleans, Louisiana, USA
- 2016 Invited talk, 20th European Society of Pigment Cell Research (ESPCR) Meeting, Milan, Italy
- 2016 Invited talk, EACR: Pezcoller Foundation Cancer Research Award lecture, Manchester, UK
- 2016 Invited talk, Splicing conference, Lisbon, Portugal

- 2015 Invited talk, 7th European Melanoma Workshop, Reykjavik, Iceland
- 2015 Invited talk, European Association for Cancer Research (EACR), Cambridge, UK
- 2015 Invited Keynote Speaker, Society for Melanoma Research, San Francisco, USA
- 2015 Invited talk, EPIGEN Chromatin Seminar, Rome, Italy
- 2015 Invited Keynote Speaker, Lorne Cancer Conference, Lorne, Australia
- 2014 Invited talk, European Melanoma Workshop, Las Palmas de Gran Canaria, Spain
- 2014 Invited keynote talk, International Society for Cellular Oncology (ISCO) and the European Workshop on Cytogenetics and Molecular Genetics of Solid Tumours (EWCMGST), Malaga, Spain
- 2013 Invited talk, European Association for Cancer Research (EACR), Cancer Genomics, Cambridge, UK
- 2013 Invited talk, 8th World Congress of Melanoma, Hamburg, Germany
- 2013 Invited talk, American Association for Cancer Research (AACR), Annual Meeting Washington, DC
- 2012 Invited talk, Panamerican Society for Pigment Cell Research Conference Annual Meeting Deer Valley, UT
- 2012 Invited talk, Nobel Forum, Karolinska Institutet, cancer symposium, Stockholm, Sweden
- 2012 Invited talk, A Nature Conference, Dermatogenetics, Miami, FL
- 2011 Invited talk, American Association for Cancer Research (AACR), Annual Meeting Orlando, FL
- 2011 Invited talk, 'state of the art' talk, Society of Investigative Dermatology, Phoenix, AZ
- 2011 Invited talk, The Washington DC Dermatological Society, Bethesda, MD
- 2010 Invited talk, American Association for Cancer Research (AACR), Cell Death Mechanisms and Cancer Therapy, San Diego, CA
- 2010 Invited talk, Advances in Genome Biology and Technology (AGBT), Marco Island, FL
- 2010 Invited talk, Keystone Conference Advances New Paradigms in Cancer Therapeutics British Columbia, Canada
- 2010 Invited talk, American Association for Cancer Research (AACR), Annual Meeting Washington, DC
- 2010 Invited talk, Annual Healthcare Conference, Boston, MA
- 2010 Gordon Research Conference Phosphorylation & G-Protein Mediated Signaling Network Biddeford, ME
- 2010 Invited talk, International Melanoma Congress, Sidney, Australia
- 2009 Invited talk, International Melanoma Congress, Boston, MA
- 2009 Gordon Research Conference Matrix Metalloproteinases, Les Diablerets, Switzerland
- 2009 National Cancer Institute, Cell Cycle Symposium, Bethesda, MD

Other seminars

- 2021 Genentech, Inc, Seminar (Host: J. Lill, Executive Director), virtual
- 2020 Vall d'Hebron Institute of Oncology Scientific Seminars Series (Host: A. Gros), virtual
- 2020 Grand Rounds, Jefferson Cancer Center, virtual

- 2020 Achilles Therapeutic seminar series (Host: S. Quezada), virtual
- 2020 Dana Farber/ Harvard Cancer Center Connect Science seminar series
- 2020 Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, Hebrew University, Dept. Seminar (Host: Y. Drier), Jerusalem, Israel
- 2019 Center of excellence in immunology, NCI, Bethesda, USA
- 2019 Ichilov, Dept. Seminar (Host: Y. Bogoch), Tel Aviv, Israel
- 2019 The Youdim Family Prize for Excellence in Cancer Research, Haifa, Israel
- 2019 the Department of Pathology, Tel Aviv University, Dept. Seminar (Host: N. Erez), Tel Aviv
- 2019 Department of Biochemistry & Molecular Biology, Tel Aviv University
- 2018 Technion Integrated Cancer Center, Dept. Seminar (Host: Z. Ronai), Haifa, Israel
- 2017 Dept. of Microbiology Immunology and Genetics, Dept. Seminar (Host: M. Elkabetz), Ben Gurion, Israel
- 2017 MICC-TICC Symposium, Rehovot, Israel
- 2017 Weizmann-DKFZ meeting, Rehovot, Israel
- 2016 WIS-NKI meeting, Rehovot, Israel
- 2016 Netherlands Cancer Institute (NKI), Dept. Seminar (Host: T. Schumacher) Amsterdam, Holland
- 2016 Department of Human Biology, Haifa University, Dept. Seminar (Host: M. Kosloff), Haifa, Israel
- 2015 Cancer Research UK Manchester Institute external seminar series, Dept. Seminar (Host: R. Marais & J. Brognard), Manchester, UK
- 2015 Cell Communication in Translational Research conference, Rehovot, Israel
- 2015 Cancer Research UK Cambridge Institute distinguished lecturer series, Dept. Seminar (Host: N. Rosenfeld), Cambridge, UK
- 2015 Department for developmental biology and cancer research, Hebrew University, Dept. Seminar (Host: A. Ben-Zvi), Jerusalem, Israel
- 2014 Israel Society for Cancer Research, Haifa, Israel
- 2014 Weizmann Institute of Science- VALL D'HEBRON, Institute of Oncology joint symposium
- 2014 SignGene, Frontiers in Cell Signaling and Gene Regulation, Haifa, Israel
- 2014 Sheba Medical Center, Dept. Seminar (Host: D. Avni), Tel Aviv, Israel
- 2014 Faculty of Agriculture, Food, and Environment, Dept. Seminar (Ido Braslavsky), Rehovot, Israel
- 2014 Frontiers of Science seminar series, Dept. Seminar (Host: K. Elenius), Turku, Finland
- 2014 Department of Molecular Microbiology, Technion, Dept. Seminar (Host: D. Kornitzer), Haifa, Israel
- 2014 Faculty of life Sciences, Bar Ilan University, Dept. Seminar (Host: E. Levanon), Tel Aviv, Israel
- 2013 TRON, Seminar (Host: U. Sahin), Mainz, Germany
- 2013 IRCC - Institute for Cancer Research and Treatment, Dept. Seminar (Host: A. Bardelli), Torino, Italy
- 2013 Europhosphatase meeting, Rehovot, Israel
- 2013 Department of Human Genetics and Biochemistry, Tel Aviv University, Dept. Seminar (Host: C. Levy), Tel Aviv, Israel

- 2013 Genetics Department at the Hebrew University, Dept. Seminar (Host: A. Zaslaver), Jerusalem, Israel
- 2012 Dermatology Department, Yale University, Dept. Seminar (Host: R. Halaban), New Haven, CT
- 2012 Dana-Farber /Harvard, Seminars in Oncology Lecture Series, (Host: L. Garraway), Boston, MA
- 2012 National Institutes of Health Clinical Center, Grand Rounds Bethesda, MD
- 2011 Memorial Sloan-Kettering, Dept. Seminar (Host: C. Sawyers and D. Solit). New York, NY
- 2011 International Skin Carcinogenesis Conference (declined), Ohio, USA
- 2010 M. D. Anderson Cancer Center, Dept. Seminar (Host: M. Bar Eli), Houston, TX
- 2010 Novartis Institutes for Biomedical Research, Seminar (Host: Dale Porter), Boston, MA, USA
- 2010 Cleveland Clinic, Dept. Seminar (Host: C. Eng), Cleveland. OH, USA
- 2010 Surgery Branch, National Cancer Institute, Dept. Seminar (Host: S. Rosenberg), MD, USA
- 2010 Sanford Burnham Medical Research Institute, Dept. Seminar (Host: Z. Ronai), CA, USA
- 2009 Genentech, Inc, Seminar (Host: D. Stokoe), San Francisco, CA, USA
- 2009 Moffitt Cancer Center Dept. Seminar (Host: J. Webber), Tampa, FL, USA
- 2009 Duke University Medical Center, Grand Rounds (Host: R. McLendon), Durham, NC, USA
- 2009 Duke University Medical Center, Dept. Seminar (Host: J. Nevins), Durham, NC, USA
- 2009 The Wellcome Trust Sanger Institute Seminar (Host: M. Stratton), Cambridge, UK
- 2009 Ludwig Institute for Cancer Research Seminar (Host: X. Lu), Oxford, UK
- 2009 Johns Hopkins University, Seminar (Host: R. Alani), Baltimore, MD, USA

G. SCIENTIFIC PRODUCTIVITY

Competitive National and International Grants since arrival to Weizmann (2013)

2022-2025	Melanoma Research Alliance (#917324)(Smith, Bianchet, Samuels) <i>Identifying public neoantigens, their TCRs and their rules of engagement</i>	\$900,000
2020-2022	ICRF (Samuels and Yuan) <i>Identifying PIK3CA neoantigen-specific T cell receptors for cell therapy of solid tumors</i>	\$220,000
2021-2024	Middle East Cooperation grant, German Research Council (DFG) <i>Rationally designed cancer vaccines from a better understanding of the interaction between neopeptide-specific T cells and intratumoral heterogeneity</i>	318,000€
2020-2025	H2020-FET-OPEN (964998) DECOD-Ag	418,000€
2019-2022	Melanoma Research Alliance Established Investigator Award <i>Studying the effects of intra-tumor heterogeneity on anti-tumor immunity</i>	375,000\$
2019-2021	Fundación Ramón Areces (with M. Soengras) <i>Heterogeneity in melanoma metastasis and resistance to immune checkpoint blockade</i>	300,000€
2018-2023	ERC Consolidator Grant, EU-H2020-ERC-CoG, (770854)	2,000,000€

Mel-Interactions

2017-2022	Israel Science Foundation (712811) <i>Multifaceted analysis of genetically altered signaling hubs in melanoma</i>	300,000₪
2016-2019	Melanoma Research Alliance (712422)(Wargo, Straussman, Admon) <i>Identifying Somatic and Microbial Neo-antigens Associated with Melanoma Responses</i>	\$900,000
2013-2018	ERC StG grant of the EU (335377) <i>MELGEN</i>	1,500,000€
2016-2018	Minerva Foundation (712294) <i>Systematic analysis of melanoma driver mutations in genetically engineered mouse models</i>	150,000€
2017-2018	Rising Tide Foundation <i>Combined signatures of neoantigens and T cell receptors as biomarkers for patient stratification in melanoma immunotherapies</i>	100,000\$
2017-2018	EU-ERC-POC (754282) <i>INTACT</i>	150,000€
2013-2017	Israel Science Foundation (877/13) <i>Systematic Biological and Biochemical Analysis of Somatic Mutated Genes in Melanoma Employing Somatic Cell Knockout and Endogenous Epitope Tagging Technologies</i>	300,000₪
2015-2017	EU-ERC-POC (677645) <i>COMbAT</i>	150,000€
2014-2016	Internal Weizmann grant, Weizmann-UK (co-PI Xin Lu) <i>A systematic genetic and functional analysis to characterize MAGEC1 as a novel melanoma oncogene</i>	25,000\$
2013-2016	Internal Weizmann grant, Gruber Peter&Patricia award <i>Identification of targetable targets in melanoma</i>	150,000\$
2014-2015	Rising Tide Foundation (with U. Alon) <i>Rational design of personalized multi-drug cocktails using a small number of measurements on patient derived tumor material</i>	150,000\$
2013-2015	Weizmann-Jefferson Collaborative Program (co PI E. Domany, A. Aplin) <i>Acquired resistance to next-generation RAF inhibitors in mutant BRAF melanoma</i>	35,000\$
2013-2014	ISF-Equipment	84,100\$
2013-2014	Rising Tide Foundation (with I. Sagi) <i>Novel experimental therapies to treat ERBB4 mutated melanoma patients</i>	
2013-2014	Internal Weizmann grant, Benedetti Found.-Cherasco (co-PI A. Bardelli)	32,000\$

A systematic genetic and functional analysis to characterize RASA2 as a novel melanoma tumor suppressor gene

Competitive National and International Grants (while at NIH 2006-2012)

2010-2011	Eli Lilly <i>Whole Genome/Exome Sequencing of Melanoma</i>	250,000\$
2008-2010	The Harry J. Lloyd Charitable Trust <i>Mutational analysis of the phosphatase gene family in cutaneous malignant melanoma</i>	84,000\$
2008-2010	NIH Bench-to-Bedside Award <i>Predicting the response to treatment using gene mutation profiling in metastatic melanoma patients</i>	100,000\$

NIH intramural funding

2006-2011	Base allocation per year	600,500\$
-----------	--------------------------	-----------

NIH competitive supplements

2009	\$70,000
2010	\$320,000
2011	\$50,000

Clinical Trial-Phase II

A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring *ERBB4* Mutations (Associate Investigator: Yarden Samuels, Ph.D.)

Protocol number: Clinical Center number 11-C-0048; NCI Protocol number P8786

REFEREED ARTICLES

- 1 Avraham, A., Jung, S., Samuels, Y., Seger, R. & Ben-Neriah, Y. Co-stimulation-dependent activation of a JNK-kinase in T lymphocytes. *Eur J Immunol* 28, 2320-2330 (1998) [\[URL\]](#)
Impact factor: 5.1; Citations 65.
- 2 Almog, R., Low, M., Cohen, D., Robin, G., Ashkenazi, S., Bercovier, H., Gdalevich, M., Samuels, Y., Ashkenazi, I., Shemer, J., Eldad, A. & Green, M. S. Prevalence of anti-hepatitis A antibodies, hepatitis B viral markers, and anti-hepatitis C antibodies among immigrants from the former USSR who arrived in Israel during 1990-1991. *Infection* 27, 212-217 (1999). **Impact factor: 2.6; Citations 15.**
- 3 Samuels-Lev, Y*, O'Connor, D. J. *, Bergamaschi, D. *, Trigiante, G., Hsieh, J. K., Zhong, S., Campargue, I., Naumovski, L., Crook, T. & Lu, X. ASPP proteins specifically stimulate the apoptotic function of p53. *Mol Cell* 8, 781-794 (2001). [\[URL\]](#). (*co-first authors).
Impact factor: 14.2; Citations 513.
Highlighted in *Nature Reviews Cancer* and in News and Views in *Nature*

- 4 Bergamaschi, D*, Samuels, Y*, O'Neil, N. J., Trigianti, G., Crook, T., Hsieh, J. K., O'Connor, D. J., Zhong, S., Campargue, I., Tomlinson, M. L., Kuwabara, P. E. & Lu, X. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. *Nat Genet* 33, 162-167, doi:10.1038/ng1070 (2003).(*co-first authors). [\[URL\]](#)
Impact factor: 27.1; Citations 277.
- 5 Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., Peters, B. A., Velculescu, V. E. & Park, B. H. The PIK3CA gene is mutated with high frequency in human breast cancers. *Cancer Biol Ther* 3, 772-775 (2004).[\[URL\]](#)
Impact factor: 3.3; Citations 493.
- 6 Bergamaschi, D*, Samuels, Y*, Jin, B., Duraisingham, S., Crook, T. & Lu, X. ASPP1 and ASPP2: common activators of p53 family members. *Mol Cell Biol* 24, 1341-1350 (2004).[\[URL\]](#) (*co-first authors).
Impact factor: 3.8; Citations 194.
- 7 Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y. R., Cummins, J. M., McLendon, R. E., Fults, D. W., Velculescu, V. E., Bigner, D. D. & Yan, H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. *Cancer Res* 64, 5048-5050, doi:10.1158/0008-5472.CAN-04-1170 (2004).[\[URL\]](#)
Impact factor: 9.1; Citations 261.
- 8 Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B. & Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 304, 554, doi:10.1126/science.1096502 (2004).[\[URL\]](#)
Impact factor: 37.2; Citations ,2577.
- 9 Bergamaschi, D., Samuels, Y., Zhong, S. & Lu, X. Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation. *Oncogene* 24, 3836-3841, doi:10.1038/sj.onc.1208535 (2005).[\[URL\]](#)
Impact factor: 8.4; Citations 9.
- 10 Parsons, D. W., Wang, T. L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., Lengauer, C. & Velculescu, V. E. Colorectal cancer: mutations in a signalling pathway. *Nature* 436, 792, doi:10.1038/436792a (2005).[\[URL\]](#)
Impact factor: 40.1; Citations 453.
- 11 Samuels, Y., Diaz, L. A., Jr., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., Vogelstein, B. & Velculescu, V. E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. *Cancer Cell* 7, 561-573, doi:10.1016/j.ccr.2005.05.014 (2005).[\[URL\]](#)
Impact factor: 27.4; Citations 679.

- 12 Bergamaschi, D. , Samuels, Y. , Sullivan, A., Zvelebil, M., Breyssens, H., Bisso, A., Del Sal, G., Syed, N., Smith, P., Gasco, M., Crook, T. & Lu, X. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. *Nat Genet* 38, 1133-1141, doi:10.1038/ng1879 (2006).[\[URL\]](#)
Impact factor: 27.1; Citations 198.
- 13 Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T. L. & Shih Ie, M. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. *Cancer Biol Ther* 5, 779-785 (2006).[\[URL\]](#)
Impact factor: 3.3; Citations 135.
- 14 Huang, C. H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B. & Amzel, L. M. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. *Science* 318, 1744-1748, doi:10.1126/science.1150799 (2007).[\[URL\]](#)
Impact factor: 37.2; Citations 377.
- 15 Rago, C., Huso, D. L., Diehl, F., Karim, B., Liu, G., Papadopoulos, N., Samuels, Y., Velculescu, V. E., Vogelstein, B., Kinzler, K. W. & Diaz, L. A., Jr. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. *Cancer Res* 67, 9364-9370, doi:10.1158/0008-5472.CAN-07-0605 (2007).[\[URL\]](#)
Impact factor: 9.1; Citations 105.
- 16 Solomon, D. A., Kim, J. S., Cronin, J. C., Sibenaller, Z., Ryken, T., Rosenberg, S. A., Ransom, H., Jean, W., Bigner, D., Yan, H., Samuels, Y. & Waldman, T. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. *Cancer Res* 68, 10300-10306, doi:10.1158/0008-5472.CAN-08-3272 (2008).[\[URL\]](#)
Impact factor: 9.1; Citations 92.
- 17 Cronin, J. C., Wunderlich, J., Loftus, S. K., Prickett, T. D., Wei, X., Ridd, K., Vemula, S., Burrell, A. S., Agrawal, N. S., Lin, J. C., Banister, C. E., Buckhaults, P., Rosenberg, S. A., Bastian, B. C., Pavan, W. J. & Samuels, Y. Frequent mutations in the MITF pathway in melanoma. *Pigment Cell Melanoma Res* 22, 435-444, doi:10.1111/j.1755-148X.2009.00578.x (2009).[\[URL\]](#)
Impact factor: 4.6; Citations 104.
- 18 Palavalli, L. H., Prickett, T. D., Wunderlich, J. R., Wei, X., Burrell, A. S., Porter-Gill, P., Davis, S., Wang, C., Cronin, J. C., Agrawal, N. S., Lin, J. C., Westbrook, W., Hoogstraten-Miller, S., Molinolo, A. A., Fetsch, P., Filie, A. C., O'Connell, M. P., Banister, C. E., Howard, J. D., Buckhaults, P., Weeraratna, A. T., Brody, L. C., Rosenberg, S. A. & Samuels, Y. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. *Nat Genet* 41, 518-520, doi:10.1038/ng.340 (2009).[\[URL\]](#)
Impact factor: 27.1; Citations 107.
- 19 Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A. & Samuels, Y. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. *Nat Genet* 41, 1127-1132, doi:10.1038/ng.438 (2009).[\[URL\]](#)
Impact factor: 27.1; Citations 246.

Previewed in *Cancer Cell*

- 20 Solomon, D. A., Kim, J. S., Yang, X. R., Tucker, M. A., Goldstein, A. M., Samuels, Y. & Waldman, T. Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome. *Pigment Cell Melanoma Res* 22, 489-491, doi:10.1111/j.1755-148X.2009.00587.x (2009).[\[URL\]](#)
Impact factor: 4.6; Citations 4.

- 21 Cardenas-Navia, L. I., Cruz, P., Lin, J. C., Program, N. C. S., Rosenberg, S. A. & Samuels, Y. Novel somatic mutations in heterotrimeric G proteins in melanoma. *Cancer Biol Ther* 10, 33-37 (2010).[\[URL\]](#)
Impact factor: 3.3; Citations 12.

- 22 Ericson, K., Gan, C., Cheong, I., Rago, C., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Huso, D. L., Vogelstein, B. & Papadopoulos, N. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. *Proc Natl Acad Sci U S A* 107, 2598-2603, doi:10.1073/pnas.0914018107 (2010).[\[URL\]](#)
Impact factor: 9.6; Citations 92.

- 23 Lopez, G. Y., Reitman, Z. J., Solomon, D., Waldman, T., Bigner, D. D., McLendon, R. E., Rosenberg, S. A., Samuels, Y. & Yan, H. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. *Biochem Biophys Res Commun* 398, 585-587, doi:10.1016/j.bbrc.2010.06.125 (2010).[\[URL\]](#)
Impact factor: 2.4; Citations 33.

- 24 Wei, X., Prickett, T. D., Vitoria, C. G., Molinolo, A., Lin, J. C., Cardenas-Navia, I., Cruz, P., Program, N. C. S., Rosenberg, S. A., Davies, M. A., Gershenwald, J. E., Lopez-Otin, C. & Samuels, Y. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. *Mol Cancer Res* 8, 1513-1525, doi:10.1158/1541-7786.MCR-10-0262 (2010).[\[URL\]](#)
Impact factor: 4.5; Citations 33.

- 25 Prickett, T. D., Wei, X., Cardenas-Navia, I., Teer, J. K., Lin, J. C., Walia, V., Gartner, J., Jiang, J., Cherukuri, P. F., Molinolo, A., Davies, M. A., Gershenwald, J. E., Stemke-Hale, K., Rosenberg, S. A., Margulies, E. H. & Samuels, Y. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. *Nat Genet* 43, 1119-1126, doi:10.1038/ng.950 (2011).[\[URL\]](#)
Impact factor: 27.1; Citations 105.
Highlighted in Research Watch in *Cancer Discovery* and in *Pigment Cell Melanoma Res*

- 26 Solomon, D. A., Kim, T., Diaz-Martinez, L. A., Fair, J., Elkahouloun, A. G., Harris, B. T., Toretzky, J. A., Rosenberg, S. A., Shukla, N., Ladanyi, M., Samuels, Y., James, C. D., Yu, H., Kim, J. S. & Waldman, T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. *Science* 333, 1039-1043, doi:10.1126/science.1203619 (2011).[\[URL\]](#)

Impact factor: 37.2; Citations 302.

- 27 Wei, X., Moncada-Pazos, A., Cal, S., Soria-Valles, C., Gartner, J., Rudloff, U., Lin, J. C., Program, N. C. S., Rosenberg, S. A., Lopez-Otin, C. & Samuels, Y. Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. *Hum Mutat* 32, E2148-2175, doi:10.1002/humu.21477 (2011).[\[URL\]](#)

Impact factor: 5.3; Citations 28.

- 28 Wei, X., Walia, V., Lin, J. C., Teer, J. K., Prickett, T. D., Gartner, J., Davis, S., Program, N. C. S., Stemke-Hale, K., Davies, M. A., Gershenwald, J. E., Robinson, W., Robinson, S., Rosenberg, S. A. & Samuels, Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. *Nat Genet* 43, 442-446, doi:10.1038/ng.810 (2011).[\[URL\]](#)

Impact factor: 27.1; Citations 340.

Highlighted on the journal cover and in *Nat Rev Clin Oncol*

- 29 Gartner, J. J., Davis, S., Wei, X., Lin, J. C., Trivedi, N. S., Teer, J. K., Program, N. C. S., Meltzer, P. S., Rosenberg, S. A. & Samuels, Y. Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. *BMC Genomics* 13, 505, doi:10.1186/1471-2164-13-505 (2012).[\[URL\]](#)

Impact factor: 3.7; Citations 18.

- 30 Parker, S. C., Gartner, J., Cardenas-Navia, I., Wei, X., Ozel Abaan, H., Ajay, S. S., Hansen, N. F., Song, L., Bhanot, U. K., Killian, J. K., Gindin, Y., Walker, R. L., Meltzer, P. S., Mullikin, J. C., Furey, T. S., Crawford, G. E., Rosenberg, S. A., Samuels, Y. & Margulies, E. H. Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes. *PLoS Genet* 8, e1002871, doi:10.1371/journal.pgen.1002871 (2012). (Samuels Y is a co-corresponding author)[\[URL\]](#)

Impact factor: 5.5; Citations 8.

- 31 Gartner, J. J., Parker, S. C., Prickett, T. D., Dutton-Regester, K., Stitzel, M. L., Lin, J. C., Davis, S., Simhadri, V. L., Jha, S., Katagiri, N., Gotea, V., Teer, J. K., Wei, X., Morken, M. A., Bhanot, U. K., Program, N. C. S., Chen, G., Elnitski, L. L., Davies, M. A., Gershenwald, J. E., Carter, H., Karchin, R., Robinson, W., Robinson, S., Rosenberg, S. A., Collins, F. S., Parmigiani, G., Komar, A. A., Kimchi-Sarfaty, C., Hayward, N. K., Margulies, E. H. & Samuels, Y. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. *Proc Natl Acad Sci U S A* 110, 13481-13486, doi:10.1073/pnas.1304227110 (2013).[\[URL\]](#)

Impact factor: 9.6; Citations 112.

Highlighted in Research Watch in *Cancer Discovery*

- 32 Hansen, N. F., Gartner, J. J., Mei, L., Samuels, Y. & Mullikin, J. C. Shimmer: detection of genetic alterations in tumors using next-generation sequence data. *Bioinformatics* 29, 1498-1503, doi:10.1093/bioinformatics/btt183 (2013).[\[URL\]](#)

Impact factor: 5.4; Citations 35.

- 33 Lu, Y. C., Yao, X., Li, Y. F., El-Gamil, M., Dudley, M. E., Yang, J. C., Almeida, J. R., Douek, D. C., Samuels, Y., Rosenberg, S. A. & Robbins, P. F. Mutated PPP1R3B is recognized by T cells

used to treat a melanoma patient who experienced a durable complete tumor regression. *J Immunol* 190, 6034-6042, doi:10.4049/jimmunol.1202830 (2013).[\[URL\]](#)

Impact factor: 4.5; Citations 90.

- 34 Robbins, P. F., Lu, Y. C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., Samuels, Y. & Rosenberg, S. A. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. *Nat Med* 19, 747-752, doi:10.1038/nm.3161 (2013).[\[URL\]](#)

Impact factor: 32.6; Citations 690.

- 35 Dutton-Regester, K., Gartner, J. J., Emmanuel, R., Qutob, N., Davies, M. A., Gershenwald, J. E., Robinson, W., Robinson, S., Rosenberg, S. A., Scolyer, R. A., Mann, G. J., Thompson, J. F., Hayward, N. K. & Samuels, Y. A highly recurrent RPS27 5'UTR mutation in melanoma. *Oncotarget* 5, 2912-2917, doi:10.18632/oncotarget.2048 (2014).[\[URL\]](#)

Impact factor: 5.1; Citations 34.

- 36 Lu, Y. C., Yao, X., Crystal, J. S., Li, Y. F., El-Gamil, M., Gross, C., Davis, L., Dudley, M. E., Yang, J. C., Samuels, Y., Rosenberg, S. A. & Robbins, P. F. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. *Clin Cancer Res* 20, 3401-3410, doi:10.1158/1078-0432.CCR-14-0433 (2014).[\[URL\]](#)

Impact factor: 4.5; Citations 207.

- 37 Martin, D., Abba, M. C., Molinolo, A. A., Vitale-Cross, L., Wang, Z., Zaida, M., Delic, N. C., Samuels, Y., Lyons, J. G. & Gutkind, J. S. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. *Oncotarget* 5, 8906-8923, doi:10.18632/oncotarget.2417 (2014).[\[URL\]](#)

Impact factor: 5.1; Citations 100.

- 38 Prickett, T. D., Zerlanko, B., Gartner, J. J., Parker, S. C. J., Dutton-Regester, K., Lin, J. C., Teer, J. K., Wei, X., Jiang, J., NISC Comparative Sequencing, P., Chen, G., Davies, M. A., Gershenwald, J. E., Robinson, W., Robinson, S., Hayward, N. K., Rosenberg, S. A., Margulies, E. H. & Samuels, Y. Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. *J Invest Dermatol* 134, 452-460, doi:10.1038/jid.2013.365 (2014).[\[URL\]](#)

Impact factor: 8.5; Citations 14.

- 39 Prickett, T. D., Zerlanko, B. J., Hill, V. K., Gartner, J. J., Qutob, N., Jiang, J., Simaan, M., Wunderlich, J., Gutkind, J. S., Rosenberg, S. A. & Samuels, Y. Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation. *J Invest Dermatol* 134, 2390-2398, doi:10.1038/jid.2014.190 (2014).[\[URL\]](#)

Impact factor: 8.5; Citations 16.

- 40 Walia, V., Prickett, T. D., Kim, J. S., Gartner, J. J., Lin, J. C., Zhou, M., Rosenberg, S. A., Elble, R. C., Solomon, D. A., Waldman, T. & Samuels, Y. Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma. *Hum Mutat* 35, 1301-1310, doi:10.1002/humu.22630 (2014).[\[URL\]](#)

Hum Mutat, 2014. **Impact factor: 5.3; Citations 16.**

- 41 Arafah, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahouloun, A., Wilmott, J. S., Gartner, J. J., Di Pizio, A., Winograd-Katz, S., Sindiri, S., Rotkopf, R., Dutton-Regester, K., Johansson, P., Pritchard, A. L., Waddell, N., Hill, V. K., Lin, J. C., Hevroni, Y., Rosenberg, S. A., Khan, J., Ben-Dor, S., Niv, M. Y., Ulitsky, I., Mann, G. J., Scolyer, R. A., Hayward, N. K. & Samuels, Y. Recurrent inactivating RASA2 mutations in melanoma. *Nat Genet* 47, 1408-1410, doi:10.1038/ng.3427 (2015).[\[URL\]](#)
Impact factor: 27.1; Citations 53.
- 42 Cancer Genome Atlas, N. Genomic Classification of Cutaneous Melanoma. *Cell* 161, 1681-1696, doi:10.1016/j.cell.2015.05.044 (2015).[\[URL\]](#)
Impact factor: 31.3; Citations 1435.
- 43 Kim, H., Frederick, D. T., Levesque, M. P., Cooper, Z. A., Feng, Y., Krepler, C., Brill, L., Samuels, Y., Hayward, N. K., Perlina, A., Piris, A., Zhang, T., Halaban, R., Herlyn, M. M., Brown, K. M., Wargo, J. A., Dummer, R., Flaherty, K. T. & Ronai, Z. A. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. *Cell Rep* 11, 1458-1473, doi:10.1016/j.celrep.2015.04.049 (2015).[\[URL\]](#)
Impact factor: 8.2; Citations 27.
- 44 Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., He, T., Shi, X., Gerszten, R. E., Zhang, Y., Yeh, J. J., Curry, W. T., Zhao, D., Sundaram, S., Nigim, F., Koerner, M. V. A., Ho, Q., Fisher, D. E., Roider, E. M., Kemeny, L. V., Samuels, Y., Flaherty, K. T., Batchelor, T. T., Chi, A. S. & Cahill, D. P. Extreme Vulnerability of IDH1 Mutant Cancers to NAD⁺ Depletion. *Cancer Cell* 28, 773-784, doi:10.1016/j.ccell.2015.11.006 (2015).[\[URL\]](#)
Impact factor: 27.4; Citations 199.
- 45 Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B. J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., Xiang, M., Xu, C., Fink, S., Meropol, N. J., Xu, Y., Conlon, R. A., Markowitz, S., Kinzler, K. W., Velculescu, V. E., Brunengraber, H., Willis, J. E., LaFramboise, T., Hatzoglou, M., Zhang, G. F., Vogelstein, B. & Wang, Z. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. *Nat Commun* 7, 11971, doi:10.1038/ncomms11971 (2016).[\[URL\]](#)
Impact factor: 11.8; Citations 83.
- 46 Inzelberg, R., Samuels, Y., Azizi, E., Qutob, N., Inzelberg, L., Domany, E., Schechtman, E. & Friedman, E. Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. *Neurol Genet* 2, e70, doi:10.1212/NXG.000000000000070 (2016).[\[URL\]](#)
Impact factor: 8.3; Citations 11.
- 47 Kalaora, S., Barnea, E., Merhavi-Shoham, E., Qutob, N., Teer, J. K., Shimony, N., Schachter, J., Rosenberg, S. A., Besser, M. J., Admon, A. & Samuels, Y. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. *Oncotarget* 7, 5110-5117, doi:10.18632/oncotarget.6960 (2016).[\[URL\]](#)
Impact factor: 5.1; Citations 88.

- 48 Levin, L., Srour, S., Gartner, J., Kapitansky, O., Qutob, N., Dror, S., Golan, T., Dayan, R., Brener, R., Ziv, T., Khaled, M., Schueler-Furman, O., Samuels, Y. & Levy, C. Parkin Somatic Mutations Link Melanoma and Parkinson's Disease. *J Genet Genomics* 43, 369-379, doi:10.1016/j.jgg.2016.05.005 (2016).[\[URL\]](#)
Impact factor: 4.0; Citations 7.
- 49 Revach, O. Y., Winograd-Katz, S. E., Samuels, Y. & Geiger, B. The involvement of mutant Rac1 in the formation of invadopodia in cultured melanoma cells. *Exp Cell Res* 343, 82-88, doi:10.1016/j.yexcr.2016.02.003 (2016).[\[URL\]](#)
Impact factor: 3.2; Citations 18.
- 50 Arafeh, R., Flores, K., Keren-Paz, A., Maik-Rachline, G., Gutkind, N., Rosenberg, S., Seger, R. & Samuels, Y. Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells. *Sci Rep* 7, 16345, doi:10.1038/s41598-017-16558-0 (2017).[\[URL\]](#)
Impact factor: 4.1; Citations 10.
Correction: 2019 Mar 12;9(1):4672. doi: 10.1038/s41598-018-37931-7.
- 51 Alon, M., Arafeh, R., Lee, J. S., Madan, S., Kalaora, S., Nagler, A., Abgarian, T., Greenberg, P., Rupp, E. & Samuels, Y. CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma. *Oncotarget* 9, 31264-31277, doi:10.18632/oncotarget.25805 (2018).[\[URL\]](#)
Impact factor: 5.1.
Correction: 2019 Feb 12;10(13):1344. doi: 10.18632/oncotarget.26685.
- 52 Alon, M., Emmanuel, R., Qutob, N., Bakhman, A., Peshti, V., Brodezk, A., Bassan, D., Kosloff, M. & Samuels, Y. Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma. *Pigment Cell Melanoma Res* 31, 641-648, doi:10.1111/pcmr.12705 (2018).[\[URL\]](#)
Impact factor: 4.6.
- 53 Arafeh, R., Di Pizio, A., Elkahlon, A. G., Dym, O., Niv, M. Y. & Samuels, Y. RASA2 and NF1; two-negative regulators of Ras with complementary functions in melanoma. *Oncogene*, doi:10.1038/s41388-018-0578-4 (2018).[\[URL\]](#)
Impact factor: 8.4; Citations 1.
- 54 Kalaora, S., Wolf, Y., Feferman, T., Barnea, E., Greenstein, E., Reshef, D., Tirosh, I., Reuben, A., Patkar, S., Levy, R., Quinkhardt, J., Omokoko, T., Qutob, N., Golani, O., Zhang, J., Mao, X., Song, X., Bernatchez, C., Haymaker, C., Forget, M. A., Creasy, C., Greenberg, P., Carter, B. W., Cooper, Z. A., Rosenberg, S. A., Lotem, M., Sahin, U., Shakh, G., Rupp, E., Wargo, J. A., Friedman, N., Admon, A. & Samuels, Y. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. *Cancer Discov* 8, 1366-1375, doi:10.1158/2159-8290.CD-17-1418 (2018).[\[URL\]](#)
Impact factor: 24.3; Citations 45.
- 55 Lee, J. S., Adler, L., Karathia, H., Carmel, N., Rabinovich, S., Auslander, N., Keshet, R., Stettner, N., Silberman, A., Agemy, L., Helbling, D., Eilam, R., Sun, Q., Brandis, A., Malitsky, S., Itkin, Yarden Samuels, Department of Molecular and Cellular Biology, Weizmann Institute of Science
Email: yarden.samuels@weizmann.ac.il
Phone: +972-8-9343631

M., Weiss, H., Pinto, S., Kalaora, S., Levy, R., Barnea, E., Admon, A., Dimmock, D., Stern-Ginossar, N., Scherz, A., Nagamani, S. C. S., Unda, M., Wilson, D. M., 3rd, Elhasid, R., Carracedo, A., Samuels, Y., Hannenhalli, S., Rupp, E. & Erez, A. Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. *Cell* 174, 1559-1570 e1522, doi:10.1016/j.cell.2018.07.019 (2018).

Impact factor: 31.3; Citations 38.

- 56 Lee, J. S., Das, A., Jerby-Arnon, L., Arafeh, R., Auslander, N., Davidson, M., McGarry, L., James, D., Amzallag, A., Park, S. G., Cheng, K., Robinson, W., Atias, D., Stossel, C., Buzhor, E., Stein, G., Waterfall, J. J., Meltzer, P. S., Golan, T., Hannenhalli, S., Gottlieb, E., Benes, C. H., Samuels, Y., Shanks, E. & Rupp, E. Harnessing synthetic lethality to predict the response to cancer treatment. *Nat Commun* 9, 2546, doi:10.1038/s41467-018-04647-1 (2018).[\[URL\]](#)

Impact factor: 14.9; Citations 19.

- 57 Martin, D., Degese, M. S., Vitale-Cross, L., Iglesias-Bartolome, R., Valera, J. L. C., Wang, Z., Feng, X., Yeerna, H., Vadmal, V., Moroishi, T., Thorne, R. F., Zaida, M., Siegle, B., Cheong, S. C., Molinolo, A. A., Samuels, Y., Tamayo, P., Guan, K. L., Lippman, S. M., Lyons, J. G. & Gutkind, J. S. Assembly and activation of the Hippo signalome by FAT1 tumor suppressor. *Nat Commun* 9, 2372, doi:10.1038/s41467-018-04590-1 (2018).[\[URL\]](#)

Impact factor: 14.9; Citations 33.

- 58 Nordlinger, A., Dror, S., Elkahouloun, A., Del Rio, J., Stubbs, E., Golan, T., Malcov, H., Prickett, T. D., Cronin, J. C., Parikh, S., Labes, S., Thomas, L., Yankovitz, G., Tabach, Y., Levy, C., Samuels, Y. & Khaled, M. Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4. *J Invest Dermatol* 138, 2216-2223, doi:10.1016/j.jid.2018.03.1524 (2018).[\[URL\]](#)

Impact factor: 6.2. Citations 2.

- 59 Qutob, N., Masuho, I., Alon, M., Emmanuel, R., Cohen, I., Di Pizio, A., Madore, J., Elkahouloun, A., Ziv, T., Levy, R., Gartner, J. J., Hill, V. K., Lin, J. C., Hevroni, Y., Greenberg, P., Brodezk, A., Rosenberg, S. A., Kosloff, M., Hayward, N. K., Admon, A., Niv, M. Y., Scolyer, R. A., Martemyanov, K. A. & Samuels, Y. RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. *Sci Rep* 8, 653, doi:10.1038/s41598-017-18851-4 (2018).[\[URL\]](#)

Impact factor: 4.1. Citations 7.

Correction: 2019 Mar 9;9(1):4523. doi: 10.1038/s41598-018-37932-6.

- 60 Yu, Y., Schleich, K., Yue, B., Ji, S., Lohneis, P., Kemper, K., Silvis, M. R., Qutob, N., van Rooijen, E., Werner-Klein, M., Li, L., Dhawan, D., Meierjohann, S., Reimann, M., Elkahouloun, A., Treitschke, S., Dorken, B., Speck, C., Mallette, F. A., Zon, L. I., Holmen, S. L., Peeper, D. S., Samuels, Y., Schmitt, C. A. & Lee, S. Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. *Cancer Cell* 33, 322-336 e328, doi:10.1016/j.ccell.2018.01.002 (2018).[\[URL\]](#)

Impact factor: 27.4; Citations 32.

- 61 Sana, G., Madigan, J. P., Gartner, J. J., Fourrez, M., Lin, J., Qutob, N., Narayan, J., Shukla, S., Ambudkar, S. V., Xia, D., Rosenberg, S. A., Gottesman, M. M., Samuels, Y. & Gillet, J. P. Exome sequencing of ABCB5 identifies recurrent melanoma mutations that result in increased

proliferative and invasive capacities. *J Invest Dermatol*, doi:10.1016/j.jid.2019.01.036 (2019). [\[URL\]](#)

Impact factor: 6.4; Citations 1.

- 62 Revach, O. Y., Sandler, O., Samuels, Y. & Geiger, B. Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates invadopodia formation in melanoma cells. *Cancer Res*, doi:10.1158/0008-5472.CAN-18-2316 (2019). [\[URL\]](#)

Impact factor: 8.3; Citations 11.

- 63 Nagler, A., Vredevogd, D. W., Alon, M., Cheng, P. F., Trabish, S., Kalaora, S., Arafah, R., Goldin, V., Levesque, M. P., Peeper, D. S. & Samuels, Y. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance towards MEK inhibition in NRAS mutant melanoma. *Pigment Cell Melanoma Res*, doi:10.1111/pcmr.12825 (2019). [\[URL\]](#)

Impact factor: 4.1.

- 64 Wolf, Y., Bartok, O., Patkar, S., Eli, G. B., Cohen, S., Litchfield, K., Levy, R., Jimenez-Sanchez, A., Trabish, S., Lee, J. S., Karathia, H., Barnea, E., Day, C. P., Cinnamon, E., Stein, I., Solomon, A., Bitton, L., Perez-Guijarro, E., Dubovik, T., Shen-Orr, S. S., Miller, M. L., Merlino, G., Levin, Y., Pikarsky, E., Eisenbach, L., Admon, A., Swanton, C., Ruppin, E. & Samuels, Y. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. *Cell* 179, 219-235 e221, doi:10.1016/j.cell.2019.08.032 (2019). [\[URL\]](#)

Impact factor: 36.2; Citations 95.

Highlighted in *Nature Review Clinical Oncology* [\[URL\]](#), *Nature Reviews Immunology* [\[URL\]](#), *Cancer Discovery* [\[URL\]](#) and *Cancer Cell* [\[URL\]](#).

- 65 Kalaora, S., J.S. Lee, E. Barnea, R. Levy, P. Greenberg, M. Alon, G. Yagel, G. Bar Eli, R. Oren, A. Peri, S. Patkar, L. Bitton, S.A. Rosenberg, M. Lotem, Y. Levin, A. Admon, E. Ruppin, and Y. Samuels, Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. *Nat Commun*, 2020. 11(1): p. 896. [\[URL\]](#).

Impact factor: 14.9; Citations 18.

66. Sadeqi Azer, E., F. Rashidi Mehrabadi, S. Malikic, X.C. Li, O. Bartok, K. Litchfield, R. Levy, Y. Samuels, A.A. Schaffer, E.M. Gertz, C.P. Day, E. Perez-Guijarro, K. Marie, M.P. Lee, G. Merlino, F. Ergun, and S.C. Sahinalp, PhISCS-BnB: a fast branch and bound algorithm for the perfect tumor phylogeny reconstruction problem. *Bioinformatics*, 2020. 36(Suppl_1): p. i169-i176. [\[URL\]](#).

Impact factor: 5.61; Citations 4

67. Yakovian, O., J. Sajman, R. Arafah, Y. Neve-Oz, M. Alon, Y. Samuels, and E. Sherman, MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters. *Cancer Res*, 2021. 81(5): p. 1279-1292. [\[URL\]](#)

Impact factor: 9.72; Citations

68. Nagler, A., S. Kalaora, C. Barbolin, A. Gangaev, S.L.C. Ketelaars, M. Alon, J. Pai, G. Benedek, Y. Yahalom-Ronen, N. Erez, P. Greenberg, G. Yagel, A. Peri, Y. Levin, A.T. Satpathy, E. Bar-Haim, N. Paran, P. Kvistborg, and Y. Samuels, Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics. *Cell Rep*, 2021. 35(13): p. 109305.[\[URL\]](#)

Yardena Samuels, Department of Molecular and Cellular Biology, Weizmann Institute of Science

Email: yardena.samuels@weizmann.ac.il

Phone: +972-8-9343631

Impact factor: 9.72; Citations

69. Bartok, O., A. Pataskar, R. Nagel, M. Laos, E. Goldfarb, D. Hayoun, R. Levy, P.R. Korner, I.Z.M. Kreuger, J. Champagne, E.A. Zaal, O.B. Bleijerveld, X. Huang, J. Kenski, J. Wargo, A. Brandis, Y. Levin, O. Mizrahi, M. Alon, S. Lebon, W. Yang, M.M. Nielsen, N. Stern-Ginossar, M. Altelaar, C.R. Berkers, T. Geiger, D.S. Peeper, J. Olweus, Y. Samuels*, and R. Agami*, Anti-tumour immunity induces aberrant peptide presentation in melanoma. *Nature*, 2021. 590(7845): p. 332-337. * co-corresponding authors [\[URL\]](#)

Impact factor: 42.77; Citations 10

Highlighted in Nature Reviews Cancer [\[URL\]](#)

70. Kalaora, S., A. Nagler, D. Nejman, M. Alon, C. Barbolin, E. Barnea, S.L.C. Ketelaars, K. Cheng, K. Vervier, N. Shental, Y. Bussi, R. Rotkopf, R. Levy, G. Benedek, S. Trabish, T. Dadosh, S. Levin-Zaidman, L.T. Geller, K. Wang, P. Greenberg, G. Yagel, A. Peri, G. Fuks, N. Bhardwaj, A. Reuben, L. Hermida, S.B. Johnson, J.R. Galloway-Pena, W.C. Shropshire, C. Bernatchez, C. Haymaker, R. Arora, L. Roitman, R. Eilam, A. Weinberger, M. Lotan-Pompan, M. Lotem, A. Admon, Y. Levin, T.D. Lawley, D.J. Adams, M.P. Levesque, M.J. Besser, J. Schachter, O. Golani, E. Segal, N. Geva-Zatorsky, E. Rupp, P. Kvistborg, S.N. Peterson, J.A. Wargo, R. Straussman, and Y. Samuels, Identification of bacteria-derived HLA-bound peptides in melanoma. *Nature*, 2021. 592(7852): p. 138-143. [\[URL\]](#)

Impact factor: 42.77; Citations 20

Highlighted in Nature News and Views[\[URL\]](#), *Nature Review Microbiology* [\[URL\]](#), *Cancer Cell* [\[URL\]](#)

71. Peri, A., E. Greenstein, M. Alon, J.A. Pai, T. Dingjan, S. Reich-Zeliger, E. Barnea, C. Barbolin, R. Levy, C. Arnedo-Pac, S. Kalaora, B. Dassa, E. Feldmesser, P. Shang, P. Greenberg, Y. Levin, G. Benedek, M.P. Levesque, D.J. Adams, M. Lotem, J.S. Wilmott, R.A. Scolyer, G.B. Jonsson, A. Admon, S.A. Rosenberg, C.J. Cohen, M.Y. Niv, N. Lopez-Bigas, A.T. Satpathy, N. Friedman, and Y. Samuels, Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. *J Clin Invest*, 2021. 131(20)[\[URL\]](#)

Impact factor: 11.8

72. Spencer, C.N., J.L. McQuade, V. Gopalakrishnan, J.A. McCulloch, M. Vetizou, A.P. Cogdill, M.A.W. Khan, X. Zhang, M.G. White, C.B. Peterson, M.C. Wong, G. Morad, T. Rodgers, J.H. Badger, B.A. Helmink, M.C. Andrews, R.R. Rodrigues, A. Morgun, Y.S. Kim, J. Roszik, K.L. Hoffman, J. Zheng, Y. Zhou, Y.B. Medik, L.M. Kahn, S. Johnson, C.W. Hudgens, K. Wani, P.O. Gaudreau, A.L. Harris, M.A. Jamal, E.N. Baruch, E. Perez-Guijarro, C.P. Day, G. Merlino, B. Pazdrak, B.S. Lochmann, R.A. Szczepaniak-Sloane, R. Arora, J. Anderson, C.M. Zobniw, E. Posada, E. Sirmans, J. Simon, L.E. Haydu, E.M. Burton, L. Wang, M. Dang, K. Clise-Dwyer, S. Schneider, T. Chapman, N.A.S. Anang, S. Duncan, J. Toker, J.C. Malke, I.C. Glitza, R.N. Amaria, H.A. Tawbi, A. Diab, M.K. Wong, S.P. Patel, S.E. Woodman, M.A. Davies, M.I. Ross, J.E. Gershenwald, J.E. Lee, P. Hwu, V. Jensen, Y. Samuels, R. Straussman, N.J. Ajami, K.C. Nelson, L. Nezi, J.F. Petrosino, P.A. Futreal, A.J. Lazar, J. Hu, R.R. Jenq, M.T. Tetzlaff, Y. Yan, W.S. Garrett, C. Huttenhower, P. Sharma, S.S. Watowich, J.P. Allison, L. Cohen, G. Trinchieri, C.R. Daniel, and J.A. Wargo, Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. *Science*, 2021. 374(6575): p. 1632-1640.

Impact factor: 41.8

73. Kacen, A., A. Javitt, M.P. Kramer, D. Morgenstern, T. Tsaban, M.D. Shmueli, G.C. Teo, F. da Veiga Leprevost, E. Barnea, F. Yu, A. Admon, L. Eisenbach, Y. Samuels, O. Schueler-Furman,

Y. Levin, A.I. Nesvizhskii, and Y. Merbl, Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors. *Nat Biotechnol*, 2022.

Impact factor: 68.1

INVITED REVIEWS

- 1 Samuels, Y. & Velculescu, V. E. Oncogenic mutations of PIK3CA in human cancers. *Cell Cycle* 3, 1221-1224, doi:10.4161/cc.3.10.1164 (2004). [\[URL\]](#)
Impact factor: 3.9; Citations 340.
- 2 Samuels, Y. & Ericson, K. Oncogenic PI3K and its role in cancer. *Curr Opin Oncol* 18, 77-82 (2006). [\[URL\]](#)
Impact factor: 3.6; Citations 377.
- 3 Lopez-Otin, C., Palavalli, L. H. & Samuels, Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. *Cell Cycle* 8, 3657-3662, doi:10.4161/cc.8.22.9956 (2009). [
Impact factor: 3.9; Citations 75.
- 4 Davies, M. A. & Samuels, Y. Analysis of the genome to personalize therapy for melanoma. *Oncogene* 29, 5545-5555, doi:10.1038/onc.2010.323 (2010). [\[URL\]](#)
Impact factor: 8.4; Citations 82.
5. Samuels, Y. & Waldman, T. Oncogenic mutations of PIK3CA in human cancers. *Curr Top Microbiol Immunol* 347, 21-41, doi:10.1007/82_2010_68 (2010). [\[URL\]](#)
Impact factor: 3; Citations 148.
- 6 Rudloff, U. & Samuels, Y. A growing family: adding mutated Erbb4 as a novel cancer target. *Cell Cycle* 9, 1487-1503, doi:10.4161/cc.9.8.11239 (2010). [\[URL\]](#)
Impact factor: 3.9; Citations 26.
- 7 Prickett, T. D. & Samuels, Y. Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. *Clin Cancer Res* 18, 4240-4246, doi:10.1158/1078-0432.CCR-11-1217 (2012). [\[URL\]](#)
Impact factor: 10.1; Citations 71.
- 8 Walia, V., Mu, E. W., Lin, J. C. & Samuels, Y. Delving into somatic variation in sporadic melanoma. *Pigment Cell Melanoma Res* 25, 155-170, doi:10.1111/j.1755-148X.2012.00976.x (2012). [\[URL\]](#)
Impact factor: 4.6; Citations 26.
- 9 Hill, V. K., Gartner, J. J., Samuels, Y. & Goldstein, A. M. The genetics of melanoma: recent advances. *Annu Rev Genomics Hum Genet* 14, 257-279, doi:10.1146/annurev-genom-091212-153429 (2013). [\[URL\]](#)
Impact factor: 8.6; Citations 63.

- 10 Gotea, V., Gartner, J. J., Qutob, N., Elnitski, L. & Samuels, Y. The functional relevance of somatic synonymous mutations in melanoma and other cancers. *Pigment Cell Melanoma Res* 28, 673-684, doi:10.1111/pcmr.12413 (2015). [\[URL\]](#)
Impact factor: 4.6; Citations 31.
- 11 Wolf, Y. & Samuels, Y. Cancer research in the era of immunogenomics. *ESMO Open* 3, e000475, doi:10.1136/esmoopen-2018-000475 (2018). [\[URL\]](#) **Citations 7.**
- 12 Arafah, R. & Samuels, Y. PIK3CA in cancer: The past 30 years. *Semin Cancer Biol*, doi:10.1016/j.semcancer.2019.02.002 (2019). [\[URL\]](#) **Impact factor: 9.6; Citations 41.**
13. Patton, E. E., Mueller, K. L., Adams, D. J., Anandasabapathy, N., Aplin, A. E., Bertolotto, C., Bosenberg, M., Ceol, C. J., Burd, C. E., Chi, P., Herlyn, M., Holmen, S. L., Karreth, F. A., Kaufman, C. K., Khan, S., Kobold, S., Leucci, E., Levy, C., Lombard, D. B., Lund, A. W., Marie, K. L., Marine, J. C., Marais, R., McMahon, M., Robles-Espinoza, C. D., Ronai, Z. A., Samuels, Y., Soengas, M. S., Villanueva, J., Weeraratna, A. T., White, R. M., Yeh, I., Zhu, J., Zon, L. I., Hurlbert, M. S. & Merlino, G. Melanoma models for the next generation of therapies. *Cancer Cell*, doi:10.1016/j.ccell.2021.01.011 (2021).
14. Kalaora, S., Nagler, A., Wargo, J. A. & Samuels, Y. Mechanisms of immune activation and regulation: lessons from melanoma. *Nat Rev Cancer* 22, 195-207, doi:10.1038/s41568-022-00442-9 (2022).
15. Wolf, Y. & Samuels, Y. Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally. *Clin Cancer Res* 28, 2994-3001, doi:10.1158/1078-0432.CCR-21-1355 (2022).

BOOK CHAPTERS

- 1 Samuels Y. Bardelli A. Lopez-Otin C. The Cancer Genome. . In DeVita VT., Lawrence TS., Rosenberg, S.A., (eds): *Cancer: Principles & Practice of Oncology, 9th ed.* Lippincott Williams & Wilkins. (2011).
- 2 Lau, C., Killian, K. J., Samuels, Y. & Rudloff, U. ERBB4 mutation analysis: emerging molecular target for melanoma treatment. *Methods Mol Biol* 1102, 461-480, doi:10.1007/978-1-62703-727-3_24 (2014). [\[URL\]](#)
- 3 Samuels Y. Bardelli A. Gartner J. Lopez-Otin C. The Cancer Genome. In DeVita VT., Lawrence TS., Rosenberg, S.A., (eds): *Cancer: Principles & Practice of Oncology, 10th ed* Lippincott Williams & Wilkins (2015).
- 4 Prickett, T. D., Gartner, J. J. & Samuels, Y. Genetic and Functional Analysis of GRIN2A in Tumor Samples. *Methods Mol Biol* 1677, 93-116, doi:10.1007/978-1-4939-7321-7_3 (2017). [\[URL\]](#)
- 5 Walia, V. & Samuels, Y. Analysis of Enzymatic Activity of Matrix Metalloproteinase (MMP) by Collagen Zymography in Melanoma. *Methods Mol Biol* 1731, 97-106, doi:10.1007/978-1-4939-7595-2_10 (2018). [\[URL\]](#)

- 6 Kalaora, S. & Samuels, Y. Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry. *Methods Mol Biol* 1884, 203-214, doi:10.1007/978-1-4939-8885-3_14 (2019).[\[URL\]](#)
- 7 Samuels, Y. Bardelli A. Wolf Y. Lopez-Otin C. The Cancer Genome. In DeVita VT., Lawrence TS., Rosenberg, S.A., (eds): *Cancer: Principles & Practice of Oncology*, 11th ed. Lippincott Williams & Wilkins, (2019).

INVITED EDITORIALS AND COMMENTARIES

- 1 Samuels, Y., Zhu, J. & Lengauer, C. Inhibiting phosphoinositide 3-kinases. *Cancer Biol Ther* 4, 546-547 (2005). [\[URL\]](#)
- 2 Rudloff, U. & Samuels, Y. TYRO3-mediated regulation of MITF: a novel target in melanoma? *Pigment Cell Melanoma Res* 23, 9-11, doi:10.1111/j.1755-148X.2009.00649.x (2010). [\[URL\]](#)
- 3 Keren-Paz, A., Emmanuel R. and Samuels Y. YAP and the drug resistance highway. *Nature Genetics* 47(3), 193-194 (2015).[\[URL\]](#)
- 4 Soussi, T., Taschner, P. E. & Samuels, Y. Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications. *Hum Mutat* 38, 339-342, doi:10.1002/humu.23163 (2017).[\[URL\]](#)

NUMBER OF CITATIONS

Total number of citations without self-citations: 14,890 (without self-citations); h-index: 48

H. PATENTS

Patents granted

1. US Patent Application Serial Number 10/343,649:
Members of a family of tumor suppressor genes, Apoptosis Stimulating Proteins of p53 (ASPP), which encode polypeptides capable of modulating the activity of p53, p63, and p73.
Patent Number: US2004228866
2. US Patent Application Serial Number WO 2005/091849
Mutations of the *PIK3CA* Gene. August 31, 2006.
Patent number US2005005193
3. US Patent Application Serial Number WO2020/234875
Identification of recurrent mutated neopeptides

Patent applications

1. Israel Patent Appl. 257894:
Identification of T cell antigens
2. Israel Patent Appl. 253642; US Provisional patent appl. PCT/IL2018/050824
Combination therapy for the treatment of cancer
3. Israeli patent application 282814
TCRS DIRECTED AT RAS-DERIVED RECURRENT NEOANTIGENS

Yardena Samuels, Department of Molecular and Cellular Biology, Weizmann Institute of Science
Email: yardena.samuels@weizmann.ac.il
Phone: +972-8-9343631

